|
시장보고서
상품코드
2008031
내분비 요법약(ETD) 시장 : 약제 유형별, 용도별, 유통 채널별, 지역별Endocrine Therapy Drugs (ETDs) Market, By Drug Type, By Application, By Distribution Channel, By Geography |
||||||
내분비 요법약(ETD) 시장은 2026년에 353억 달러로 추정되고 있으며, 2033년까지 500억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 353억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 5.10% | 2033년 시장 규모 예측 : | 500억 달러 |
인체의 내분비계는 호르몬을 통해 신진대사, 생식, 에너지 수준, 성장과 발달, 스트레스, 부상, 기분 장애에 대한 반응을 조절하고 조절합니다. 호르몬 요법이라고도 불리는 내분비 요법은 유방암, 당뇨병 등의 질환을 치료하기 위해 호르몬이나 화학물질을 보충, 차단 또는 제거하여 치료하는 것입니다. 여성의 체내에 존재하는 에스트로겐과 프로게스테론은 세포의 증식과 체내 확산을 촉진하므로 유방암을 악화시킬 수 있습니다. 유방암 치료에는 에스트로겐과 프로게스테론의 작용을 억제하여 암세포의 증식을 막는 방법과 난소가 에스트로겐과 프로게스테론을 생산하지 못하도록 난소를 절제하거나 수술하는 두 가지 내분비 요법이 사용됩니다. 유방암 치료에 사용되는 내분비치료제에는 아베마시클립(Verzenio), 아나스트로졸(Arimidex), 엑세메스탄(Aromasin), 플루베스트란트(Faslodex) 등이 있습니다.
시장 역학
당뇨병, 유방암과 같은 만성질환의 유병률 증가, 새로운 내분비 치료제 개발을 위한 R&D 활동 증가, 주요 기업의 인수 및 제휴와 같은 비유기적 성장 전략 채택 확대 등이 예측 기간 중 글로벌 내분비 치료제(ETD) 시장의 성장을 이끄는 주요 요인으로 작용할 것으로 예상됩니다. 주요 요인이 될 것으로 예상됩니다.
예를 들어 국제당뇨병연맹(IDF)의 'Diabetes Atlas 2019'에 따르면 2019년 기준 전 세계에서 20세부터 79세까지 약 4억 6,300만 명, 65세 이상 약 1억 3,600만 명이 당뇨병을 앓고 있는 것으로 추산됩니다. 또한 국제당뇨병연맹(IDF)의 'Diabetes Atlas 2019'에 따르면 코스타리카의 당뇨병 유병률은 2019년 9.1%에서 2030년까지 10.3%로 증가할 것으로 예측됩니다.
본 조사의 주요 특징.
- 이 보고서는 글로벌 내분비 치료제(ETD) 시장에 대한 상세한 분석을 제공하며, 2021년을 기준연도로 하여 예측 기간(2022-2030년) 시장 규모와 연평균 성장률(CAGR)을 제시합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하고 있는 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계의 내분비 치료제(ETD) 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 재무 실적, 제품 포트폴리오, 시장에서의 존재감, 유통 전략, 주요 발전, 전략 및 향후 계획 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 내분비 치료제(ETD) 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 내릴 수 있을 것입니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 내분비 요법약(ETD) 시장 : 약제 유형별, 2026-2033년
제5장 세계의 내분비 요법약(ETD) 시장 : 용도별, 2026-2033년
제6장 세계의 내분비 요법약(ETD) 시장 : 유통 채널별, 2026-2033년
제7장 세계의 내분비 요법약(ETD) 시장 : 지역별, 2026-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.04.30Endocrine Therapy Drugs (ETDs) Market is estimated to be valued at USD 35,300 Mn in 2026 and is expected to reach USD 50,000 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.1 % from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 35,300 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.10% | 2033 Value Projection: | USD 50,000 Mn |
The endocrine system of the human body uses hormones to control and coordinate with the human body's metabolism, reproduction, energy level, growth and development, as well as response for stress, injury, and mood disorders. Endocrine therapy, also known as hormone therapy, adds, blocks, or removes hormones/chemicals in order to treat diseases such as breast cancer, diabetes, etc. Estrogen and progesterone found in a woman's body can aggravate breast cancer as these hormones help the cells grow and spread throughout the body. Two types of endocrine therapy can be used for the treatment of breast cancer: blocking the action of estrogen and progesterone to stop them from helping cancerous cells to grow and, ablation or surgery to stop the ovary from producing estrogen and progesterone. Some of the endocrine therapy drugs used in breast cancer treatment include Abemaciclib (Verzenio), Anastrozole (Arimidex), Exemestane (Aromasin), and Fulvestrant (Faslodex), among others
Market Dynamics
The increasing prevalence of chronic diseases such as diabetes, breast cancer, and others, rising research and development activities to develop novel endocrine therapy drugs (ETDs), and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global endocrine therapy drugs (ETDs) market over the forecast period.
For instance, according to the International Federation of Diabetes Atlas 2019, around 463 million people aged 20-79 years and 136 million people aged 65 are estimated to be suffering from diabetes in 2019, globally. Moreover, according to the International Diabetes Federation Diabetes Atlas 2019, the prevalence of diabetes in Costa Rica is predicted to increase form 9.1 in 2019 to 10.3 by 2030.
Key features of the study
- This report provides an in-depth analysis of the global endocrine therapy drugs (ETDs) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global endocrine therapy drugs (ETDs) market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Novo Nordisk A/S, AstraZeneca, Generex Biotechnology, Orion Pharma AB, Sanofi, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co.,Inc., Bayer AG, Eli Lilly and Company, Abbott, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., TherapeuticsMD, Inc., Pfizer Inc., Allergan, BioSante Pharmaceuticals, Amgen Inc., Noven Pharmaceuticals, Inc., and QuatRx Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global endocrine therapy drugs (ETDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrine therapy drugs (ETDs) market
Market Segmentation
- By Drug Type
- Anti-diabetic Drugs
- Anti-osteoporosis Drugs
- Contraceptive Drugs
- Breast Cancer Drugs
- Others (Menopause Drugs, among others)
- By Application
- Diabetes
- Breast Cancer
- Osteoporosis
- Menopause
- Contraception
- Others (Gender Reassignment Surgery, Hypothyroidism, among others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players
- Novo Nordisk A/S
- AstraZeneca
- Generex Biotechnology
- Orion Pharma AB
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Hoffmann-La Roche
- Hisamitsu Pharmaceutical Co.,Inc.
- Bayer AG
- Eli Lilly and Company
- Abbott
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Merck & Co., Inc.
- TherapeuticsMD, Inc.
- Pfizer Inc.
- Allergan
- BioSante Pharmaceuticals
- Amgen Inc.
- Noven Pharmaceuticals, Inc.
- QuatRx Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Regulatory Scenario
- Market Trends
- Key Highlights
- Reimbursement Scenario
- Mergers & Acquisitions
- Epidemiology
4. Global Endocrine Therapy Drugs (ETDs) Market, By Drug Type, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Anti-diabetic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Anti-osteoporosis Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Contraceptive Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Breast Cancer Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Others (Menopause Drugs, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
5. Global Endocrine Therapy Drugs (ETDs) Market, By Application, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Osteoporosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Menopause
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Contraception
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Others (Gender Reassignment Surgery, Hypothyroidism, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
6. Global Endocrine Therapy Drugs (ETDs) Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
7. Global Endocrine Therapy Drugs (ETDs) Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- North America
- Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Generex Biotechnology
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Orion Pharma AB
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- F. Hoffmann-La Roche
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hisamitsu Pharmaceutical Co.,Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abbott
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- TherapeuticsMD, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Allergan
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioSante Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Noven Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- QuatRx Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Novo Nordisk A/S
9. Section
- References
- Research Methodology
- About us and Sales Contact
